{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T11:46:42Z","timestamp":1787917602463,"version":"build-2784847793"},"reference-count":41,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T00:00:00Z","timestamp":1691971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021555","name":"Vaccitech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021555","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["211042\/Z\/18\/Z"],"award-info":[{"award-number":["211042\/Z\/18\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jhepr.2023.100885","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T07:10:29Z","timestamp":1692342629000},"page":"100885","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2863-0835","authenticated-orcid":false,"given":"Tamsin","family":"Cargill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6347-966X","authenticated-orcid":false,"given":"Paola","family":"Cicconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benaka","family":"Karanth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1407-8568","authenticated-orcid":false,"given":"Emily","family":"Ashwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthil","family":"Chinnakannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7918-4321","authenticated-orcid":false,"given":"Sarah","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Bussey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Sorensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4307-9161","authenticated-orcid":false,"given":"Paul","family":"Klenerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9917-3363","authenticated-orcid":false,"given":"Thomas","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2023.100885_bib1","series-title":"Global hepatitis report","author":"World Health Organization","year":"2017"},{"key":"10.1016\/j.jhepr.2023.100885_bib2","series-title":"Transforming our world: the 2030 agenda for sustainable development","author":"United Nations","year":"2015"},{"key":"10.1016\/j.jhepr.2023.100885_bib3","series-title":"Global health sector strategy on viral hepatitis 2016\u20132021","author":"World Health Organization","year":"2016"},{"key":"10.1016\/j.jhepr.2023.100885_bib4","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100885_bib5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","article-title":"CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection","volume":"77","author":"Thimme","year":"2003","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhepr.2023.100885_bib6","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3389\/fimmu.2020.00849","article-title":"Pathogenetic mechanisms of T cell dysfunction in chronic HBV infection and related therapeutic approaches","volume":"11","author":"Fisicaro","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhepr.2023.100885_bib7","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S2468-1253(18)30007-4","article-title":"Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand","volume":"3","author":"Maini","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2023.100885_bib8","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jhep.2017.05.008","article-title":"Hepatitis B cure: from discovery to regulatory approval","volume":"67","author":"Lok","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100885_bib9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"Guidance for design and endpoints of clinical trials in chronic hepatitis B \u2013 Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference","volume":"72","author":"Cornberg","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100885_bib10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/cei.13614","article-title":"Therapeutic vaccination for treatment of chronic hepatitis B","volume":"205","author":"Cargill","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jhepr.2023.100885_bib11","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3390\/vaccines8020184","article-title":"The design and development of a multi-HBV antigen encoded in chimpanzee adenoviral and modified vaccinia Ankara viral vectors; a novel therapeutic vaccine strategy against HBV","volume":"8","author":"Chinnakannan","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jhepr.2023.100885_bib12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41541-020-00240-0","article-title":"Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans","volume":"5","author":"Capone","year":"2020","journal-title":"NPJ Vaccin"},{"key":"10.1016\/j.jhepr.2023.100885_bib13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3390\/vaccines10020257","article-title":"A\u00a0systematic review of T cell epitopes defined from the proteome of hepatitis B virus","volume":"10","author":"Wu","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.jhepr.2023.100885_bib14","series-title":"NCT04297917 A phase 1 monotherapy study to evaluate the safety, tolerability & immunogenicity of vaccination with candidate chimpanzee adenovirus-vectored HepB virus vaccine ChAdOx1 HBV in healthy participants & participants with chronic HepB infection","author":"Vaccitech Limited","year":"2020"},{"key":"10.1016\/j.jhepr.2023.100885_bib15","unstructured":"Good Clinical Practice Network. ICH harmonised guideline integrated addendum to ICH E6(R1): Guideline for Good Clinical Practice ICH E6(R2) ICH Consensus Guideline. Available from: https:\/\/ichgcp.net\/."},{"key":"10.1016\/j.jhepr.2023.100885_bib16","series-title":"Hepatitis B virus isolate C2_CLP(3), complete genome. GenBank: KJ173426.1","author":"GenBank","year":"2015"},{"key":"10.1016\/j.jhepr.2023.100885_bib17","doi-asserted-by":"crossref","first-page":"eaaz7715","DOI":"10.1126\/scitranslmed.aaz7715","article-title":"MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans","volume":"12","author":"Esposito","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhepr.2023.100885_bib18","series-title":"Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events, corrected version 2.1","year":"2017"},{"key":"10.1016\/j.jhepr.2023.100885_bib19","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2023.100885_bib20","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2023.100885_bib21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2023.100885_bib22","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine","volume":"385","author":"Falsey","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2023.100885_bib23","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ijid.2021.10.030","article-title":"Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1\/2 trial","volume":"114","author":"Asano","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jhepr.2023.100885_bib24","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S2468-1253(19)30344-9","article-title":"Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad","volume":"5","author":"Ghany","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2023.100885_bib25","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1016\/j.vaccine.2014.07.027","article-title":"Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study","volume":"32","author":"Gaggar","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jhepr.2023.100885_bib26","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1053\/j.gastro.2013.07.044","article-title":"The hepatitis B vaccine protects re-exposed health care workers, but does not provide sterilizing immunity","volume":"145","author":"Werner","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2023.100885_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-68226-5","article-title":"Optimized ex\u00a0vivo stimulation identifies multi-functional HBV-specific T\u00a0cells in a majority of chronic hepatitis B patients","volume":"10","author":"Chua","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2023.100885_bib28","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/liv.12530","article-title":"Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice","volume":"35","author":"Yoon","year":"2015","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.jhepr.2023.100885_bib29","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jhep.2016.05.016","article-title":"Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B","volume":"65","author":"Lok","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100885_bib30","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/j.gastro.2019.03.044","article-title":"Combined GS-4774 and tenofovir therapy can improve HBV-specific T-cell responses in patients with chronic hepatitis","volume":"157","author":"Boni","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2023.100885_bib31","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1038\/ncomms3836","article-title":"Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation","volume":"4","author":"Ewer","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2023.100885_bib32","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/gutjnl-2018-316641","article-title":"Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load","volume":"68","author":"Schuch","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2023.100885_bib33","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/gutjnl-2018-316644","article-title":"Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection","volume":"68","author":"Hoogeveen","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2023.100885_bib34","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/j.gastro.2020.04.019","article-title":"Effects of hepatitis B surface antigen on virus-specific and global T cells in patients with chronic hepatitis B virus infection","volume":"159","author":"Le Bert","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2023.100885_bib35","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/hep.28294","article-title":"Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans","volume":"63","author":"Kelly","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2023.100885_bib36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/vaccines4030027","article-title":"Highly-immunogenic virally-vectored T-cell vaccines cannot overcome subversion of the T-cell response by HCV during chronic infection","volume":"4","author":"Swadling","year":"2016","journal-title":"Vaccines"},{"key":"10.1016\/j.jhepr.2023.100885_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-33375-1","article-title":"Development of a molecular adjuvant to enhance antigen-specific CD8+ T cell responses","volume":"8","author":"Halbroth","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2023.100885_bib38","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3390\/genes9100495","article-title":"The global hepatitis B virus genotype distribution approximated from available genotyping data","volume":"9","author":"Velkov","year":"2018","journal-title":"Genes"},{"key":"10.1016\/j.jhepr.2023.100885_bib39","series-title":"A\u00a0Phase 1b\/2a, open-label study to evaluate the safety, tolerability and immunogenicity of VTP-300 with or without nivolumab in participants with chronic hepatitis B infection. NCT04778904","author":"Vaccitech Limited","year":"2021"},{"key":"10.1016\/j.jhepr.2023.100885_bib40","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2023.100885_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003856","article-title":"Enhancing virus-specific immunity in\u00a0vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection","volume":"10","author":"Liu","year":"2014","journal-title":"PLoS Pathog"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555923002161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555923002161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:34:04Z","timestamp":1762900444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555923002161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2589555923002161"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2023.100885","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2023.100885","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100885"}}